BEYONDSPRING INC (BYSI) Stock Price & Overview
NASDAQ:BYSI • KYG108301006
Current stock price
The current stock price of BYSI is 1.62 USD. Today BYSI is up by 1.25%. In the past month the price increased by 18.25%. In the past year, price increased by 20.9%.
BYSI Key Statistics
- Market Cap
- 67.91M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
BYSI Stock Performance
BYSI Stock Chart
BYSI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BYSI. When comparing the yearly performance of all stocks, BYSI turns out to be only a medium performer in the overall market: it outperformed 66.61% of all stocks.
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. Both the profitability and financial health of BYSI have multiple concerns.
BYSI Earnings
BYSI Forecast & Estimates
BYSI Groups
Sector & Classification
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BYSI Ownership
BYSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.36 | 376.832B | ||
| AMGN | AMGEN INC | 15.29 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.36 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.67 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.7 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 11.79 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
IPO: 2017-03-09
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 40
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What does BYSI do?
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Can you provide the latest stock price for BEYONDSPRING INC?
The current stock price of BYSI is 1.62 USD. The price increased by 1.25% in the last trading session.
Does BYSI stock pay dividends?
BYSI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BYSI stock?
BYSI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of BYSI stock?
BEYONDSPRING INC (BYSI) operates in the Health Care sector and the Biotechnology industry.
What is BEYONDSPRING INC worth?
BEYONDSPRING INC (BYSI) has a market capitalization of 67.91M USD. This makes BYSI a Micro Cap stock.